Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised…

Overview of attention for article published in Lancet Oncology, February 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

news: 5 news outlets
blogs: 1 blog
twitter: 41 X users

wikipedia: 3 Wikipedia pages
guideline: 2 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 102 Mendeley

So far, Altmetric has seen 7 news stories from 5 outlets.

Taking a break from TKIs unlikely to shorten survival

Pediatric News , 17 Jan 2025

The study was published online in The Lancet Oncology. The study was funded by the United Kingdom’s National Institute for…

Safely pausing or stopping treatment: could this be the future for solid tumours?

Cancer World, 12 Sep 2024

The success of treatment cessation in chronic myeloid leukaemia (CML), outlined in an earlier Cancerworld feature, is opening…

Taking a break from TKIs unlikely to shorten survival

Pediatric News , 08 Mar 2023

Patients with advanced renal cell carcinoma who are taking a tyrosine kinase inhibitor (TKI) to prolong their lives will…

TKI Treatment Breaks May Not Impact Outcomes in Renal Cell Carcinoma

Cancer Network, 07 Mar 2023

Although non-inferiority could not be determined following planned treatment cessation vs conventional continuation with a first…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 3 additional news stories.